Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder.

ABSTRACT:

Background

Gliosis is common among neuropsychiatric diseases, but the relationship between gliosis and response to therapeutics targeting effects of gliosis is largely unknown. Translocator protein total distribution volume (TSPO V_T), measured with positron emission tomography, mainly reflects gliosis in neuropsychiatric disease. Here, the primary objective was to determine whether TSPO V_T in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) predicts reduction of depressive symptoms following open-label celecoxib administration in treatment-resistant major depressive disorder.

Methods

A total of 41 subjects with treatment-resistant major depressive disorder underwent one [¹⁸F]FEPPA positron emission tomography scan to measure PF

SUBMITTER: Attwells S 

PROVIDER: S-EPMC11878442 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature